By Priscila Mayumi Kashiwabara
Biologics and biosimilars in Brazil – the strategic questions
Our partners Anderson Ribeiro, Aline Ferreira and Priscila Kashiwabara and patent specialist Marisa Momoli authored the chapter "Biologics and biosimilars in Brazil – the strategic questions". This article first appeared in IAM Life Sciences: Key issues for senior life sciences executives 2020, a supplement to IAM, published by Law Business Research – IP Division.
Click below to access the full chapter.
Back
Share:
Last by Priscila Mayumi Kashiwabara
June 8, 2022
INPI publishes communication on new sequence listing standard for patent applications in Brazil
On 7 June 2022, in the Official Gazette 2683, the Brazilian patent office published a communication regarding the new standard for submission … INPI publishes communication on new sequence listing standard for patent applications in Brazil
March 28, 2022
Brazilian PTOs publishes a technical note providing guidance on the patentability of elite events
On March 17, 2022, the BPTO released the INPI/CPAPD technical note No. 01/2022, which provides guidance on the patentability of inventions involving … Brazilian PTOs publishes a technical note providing guidance on the patentability of elite events
February 14, 2022
Life sciences patent eligibility in Latin America: a guide
Patents are critical to the life sciences industry and often spark intense and heated debate. To be successful, one key strategy that … Life sciences patent eligibility in Latin America: a guide